In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Bucks the Trend, with Early-Stage Deals

Executive Summary

Unlike many of its Big Pharma brethren, for Roche, preclinical and Phase I licensing has been a favored deal-making formula: collaborate with a small company on the development of a compound at or before clinical proof-of-concept, drive the program using its development expertise, and retain rights to follow-on products with which it can repeat the process, presumably having now lowered both compound and clinical risk. Its deal with Kosan is the latest example.
Advertisement

Related Content

Roche's Partners: Replacing, or Fuelling In-House R&D?
Antisoma Takes Refuge With Roche
GSK/Exelixis and In-Licensing: Earlier, Richer, Rarer
Big Pharma's Response to R&D Woes: More Early-Stage Compound Deals
Big Pharma's Response to R&D Woes: More Early-Stage Compound Deals
GSK/Exelixis and In-Licensing: Earlier, Richer, Rarer
Testing Drugs Against New Targets: Like Playing Blind Man's Bluff?
Testing Drugs Against New Targets: Like Playing Blind Man's Bluff?

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV001983

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel